All In Biotech

Drug Trial Radar · NCT05005403

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors With Azirkitug as a Single Agent and in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

694

Planned (sponsor's estimate)

Start

Nov 1, 2021

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which cancer cells form in the tissues of the head and neck. The purpose of this study is to assess adverse events and pharmacokinetics of azirkitug as a monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan. Bevacizumab is an approved product, while budigalimab, azirkitug, and telisotuzumab adizutecan are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of azirkitug will be explored. Each treatment arm receives a different dose of azirkitug in monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan. Approximately 694 adult participants will be enrolled in the study across approximately 80 sites worldwide. Participants will receive azirkitug as a monotherapy or in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan as an Intravenous (IV) Infusion for an estimated treatment period of up to 2 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Non-Small Cell Lung Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Micro Satellite Stable Colorectal Cancer
  • Gastric/Esophageal Cancer
  • High-Grade Serous Ovarian Cancer
  • Pancreatic Cancer
  • Triple Negative Breast Cancer

Interventions

  • AzirkitugDrug

    Intravenous (IV) Infusion

  • BudigalimabDrug

    Intravenous (IV) Infusion

  • BevacizumabDrug

    Intravenous (IV) Infusion

  • Telisotuzumab AdizutecanDrug

    Intravenous (IV) Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AE)Time frame: Up to 2 Years
  2. Maximum Observed Serum Concentration (Cmax) of AzirkitugTime frame: Up to 2 Years
  3. Time to Maximum Observed Serum Concentration (Tmax) of AzirkitugTime frame: Up to 2 Years
  4. Terminal Elimination Half-Life (t1/2) of AzirkitugTime frame: Up to 2 Years
  5. Area Under the Serum Concentration Versus Time Curve (AUC) of AzirkitugTime frame: Up to 2 Years
  6. Azirkitug Antidrug Antibody (ADA)Time frame: Up to 2 Years
  7. Azirkitug Neutralizing Antidrug Antibody (nADA)Time frame: Up to 2 Years
  8. Cmax of BudigalimabTime frame: Up to 2 Years
  9. Tmax of BudigalimabTime frame: Up to 2 Years
  10. t1/2 of BudigalimabTime frame: Up to 2 Years
  11. AUC of BudigalimabTime frame: Up to 2 Years
  12. Budigalimab ADATime frame: Up to 2 Years
  13. Budigalimab nADATime frame: Up to 2 Years
  14. Cmax of Telisotuzumab AdizutecanTime frame: Up to 2 Years
  15. Tmax of Telisotuzumab AdizutecanTime frame: Up to 2 Years
  16. t1/2 of Telisotuzumab AdizutecanTime frame: Up to 2 Years
  17. AUC of Telisotuzumab AdizutecanTime frame: Up to 2 Years
  18. Telisotuzumab Adizutecan ADATime frame: Up to 2 Years
  19. Telisotuzumab Adizutecan nADATime frame: Up to 2 Years

Locations

48 sites in 6 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center /ID# 276272

    Duarte, California · Recruiting

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589

    Irvine, California · Recruiting

  • USC Norris Comprehensive Cancer Center /ID# 279603

    Los Angeles, California · Recruiting

  • University of Illinois Hospital and Health Sciences System /ID# 251750

    Chicago, Illinois · Recruiting

  • University of Chicago Medical Center /ID# 276271

    Chicago, Illinois · Recruiting

  • Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593

    Fort Wayne, Indiana · Recruiting

  • Community Health Network, Inc. /ID# 243011

    Indianapolis, Indiana · Recruiting

  • Norton Cancer Institute /ID# 248903

    Louisville, Kentucky · Recruiting

  • START Midwest /ID# 248685

    Grand Rapids, Michigan · Recruiting

  • M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200

    Minneapolis, Minnesota · Recruiting

  • Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399

    Omaha, Nebraska · Recruiting

  • Duke Cancer Institute /ID# 276267

    Durham, North Carolina · Recruiting

  • Carolina BioOncology Institute /ID# 232597

    Huntersville, North Carolina · Recruiting

  • NEXT Oncology Austin /ID# 243005

    Austin, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center /ID# 270059

    Houston, Texas · Recruiting

  • Next Oncology Dallas /ID# 276254

    Irving, Texas · Recruiting

  • NEXT Oncology /ID# 243007

    San Antonio, Texas · Recruiting

  • South Texas Accelerated Research Therapeutics (START) /ID# 276268

    San Antonio, Texas · Recruiting

  • Start Mountain Region /ID# 276270

    West Valley City, Utah · Recruiting

  • Virginia Cancer Specialists - Fairfax /ID# 232592

    Fairfax, Virginia · Recruiting

  • Tom Baker Cancer Centre /ID# 276206

    Calgary, Alberta, Canada · Recruiting

  • Princess Margaret Cancer Centre /ID# 276275

    Toronto, Ontario, Canada · Recruiting

  • Centre Hospitalier de l'Universite de Montreal (CHUM) /ID# 276274

    Montreal, Quebec, Canada · Recruiting

  • Rambam Health Care Campus /ID# 238333

    Haifa, Israel · Recruiting

  • Shaare Zedek Medical Center /ID# 276244

    Jerusalem, Israel · Recruiting

  • Hadassah Medical Center-Hebrew University /ID# 252287

    Jerusalem, Israel · Recruiting

  • Shamir Medical Center /ID# 276238

    Beer Ya'akov, Central District, Israel · Recruiting

  • Meir Medical Center /ID# 277327

    Kefar Sava, Central District, Israel · Recruiting

  • Rabin Medical Center. /ID# 250497

    Petah Tikva, Central District, Israel · Recruiting

  • The Chaim Sheba Medical Center /ID# 238332

    Ramat Gan, Tel Aviv, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center /ID# 276591

    Tel Aviv, Tel Aviv, Israel · Recruiting

  • Aichi Cancer Center Hospital /ID# 250405

    Nagoya, Aichi-ken, Japan · Recruiting

  • National Cancer Center Hospital East /ID# 238840

    Kashiwa-shi, Chiba, Japan · Recruiting

  • Kobe University Hospital /ID# 250409

    Kobe, Hyōgo, Japan · Recruiting

  • Kansai Medical University Hospital /ID# 276805

    Hirakata-shi, Osaka, Japan · Recruiting

  • Shizuoka Cancer Center /ID# 250408

    Sunto-gun, Shizuoka, Japan · Recruiting

  • National Cancer Center Hospital /ID# 238372

    Chuo-ku, Tokyo, Japan · Recruiting

  • Wakayama Medical University Hospital /ID# 276806

    Wakayama, Wakayama, Japan · Completed

  • National Cancer Center /ID# 252290

    Goyang-si, Gyeonggido, South Korea · Recruiting

  • CHA Bundang Medical Center /ID# 252291

    Seongnam, Gyeonggido, South Korea · Recruiting

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.